What is Biocon Limited (BIOCON) share price today?

Biocon Limited (BIOCON) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/BIOCON for the latest live price, technical analysis, and AI-powered insights.

How to analyse BIOCON stock?

VestAI provides comprehensive BIOCON stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Biocon Limited in?

Biocon Limited (BIOCON) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Biocon Limited

Name: Biocon Limited (BIOCON) Financial Metrics
Creator: VestAI
License: https://www.vestai.io/terms

BIOCON

NSE· Healthcare

₹432.45

-3.80 (-0.87%)

52W Low · ₹331.0052W High · ₹447.15

Near 52W High

Market Cap

₹70610.96L Cr

Volume

34.30L

Prev Close

₹433.65

ISIN

INE376G01013

Orion Score

Fundamentals-based quality & risk · not a recommendation

48/100

Caution

Biocon Limited scores 48/100 (Caution) on the Orion Score — weak business quality (47), strong growth (72), weak balance-sheet safety (42) and rich valuation (27). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Profit converts to cash (CFO 2.4× PAT)
Low debt, comfortable interest cover
No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 5/9Altman Z Safe(4.64)Beneish M Clean(-2.41)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

73/100

Strong

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.42x — lean balance sheet

QUALITY

Low Quality

ROCE 3.5% — poor capital efficiency

MOMENTUM

Neutral

RSI 58.5 — consolidating

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio: 153.23
ROCE: 3.47%
ROE (1Y): 1.15%
D/E Ratio: 0.42x
OPM: 11.30%
TTM EPS: ₹2.83
Dividend Yield: 11.00%
Qtrly Sales: ₹4,484.30 Cr
Qtrly Profit: ₹125.90 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q4 2026	₹4,484.3	₹125.9	11.3%	₹0.79
Q3 2026	₹4,173	₹143.8	7.6%	₹1.07
Q2 2026	₹4,262.5	₹84.5	8.5%	₹0.65
Q1 2026	₹3,910.1	₹31.4	7.5%	₹0.26
Q4 2025	₹4,358.1	₹344.5	14.7%	₹2.87

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2026	₹16,779.9	₹385.6	₹3,394.9	8.9%
FY 2025	₹15,052.2	₹1,013.3	₹4,471	9.8%
FY 2024	₹14,195.8	₹1,022.5	₹4,068.4	10.1%
FY 2023	₹10,934.1	₹462.7	₹2,429.2	14.9%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
BIOCON ★	₹70,611 Cr	153.23	3.47%	1.15%	0.42x	11.30%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹88,148 Cr	25.39	12.55%	9.93%	0.21x	15.11%
ASTERDMAster DM Quality	₹68,390 Cr	104.34	8.93%	10.07%	0.46x	13.98%
ABBOTINDIAAbbott India Limited	₹59,509 Cr	38.28	36.31%	34.46%	0.04x	27.01%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹58,797.3	₹56,070.7	₹52,042.8	₹20,394
Equity	₹21,644	₹19,783.7	₹17,866.9	₹8,432.5
Total Debt	₹18,362	₹16,276.7	₹18,018.8	₹5,146.6
Cash	₹3,226.7	₹1,233.4	₹1,323.2	₹662.6
Net Debt	₹14,528.8	₹14,496.2	₹16,447.5	₹4,241.4
Working Capital	₹1,952.4	₹-179.6	₹3,823.3	₹4,554.3

Shareholding Pattern

Q1 FY2027

Promoter

54.07%

FII

14.36%

DII

11.75%

Public

19.82%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	54.07%	14.36% ↓	11.75% ↓	19.82% ↑
Q4 FY2026	54.07% ↓	15.85% ↑	12.97% ↓	17.11% ↑
Q3 FY2026	54.45%	7.39% ↑	21.67% ↓	16.34% ↓
Q2 FY2026	54.45%	6.61% ↑	22.06% ↓	16.7% ↑
Q1 FY2026	54.45% ↓	6.04% ↑	22.83% ↑	16.51% ↓
Q4 FY2025	60.64%	5.67%	15.73% ↑	17.77% ↓
Q3 FY2025	60.64%	5.66% ↓	15.36% ↑	18.11% ↓
Q2 FY2025	60.64%	5.93%	14.44%	18.74%

Corporate Actions

Ex-Date	Action	Details
2026-07-03	DIVIDEND	Dividend - Re 0.50 Per Share

Funds Holding This Stock

152 mutual fund schemes

Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct GrowthMOTILAL_OSWAL

5.09%

₹2 Cr

Tata Nifty MidSmall Healthcare Index Fund Direct GrowthTATA

5.09%

₹9 Cr

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct GrowthICICI_PRUDENTIAL

4.71%

₹304 Cr

SBI Contra Direct Plan GrowthSBI

3.63%

₹1.7K Cr

SBI Healthcare Opportunities Fund Direct Plan GrowthSBI

3.52%

₹161 Cr

ICICI Prudential Nifty Pharma Index Fund Direct GrowthICICI_PRUDENTIAL

3.43%

₹4 Cr

SBI MNC Direct Plan GrowthSBI

3.25%

₹197 Cr

LIC MF Healthcare Fund Direct GrowthLIC

3.06%

₹3 Cr

Helios Arbitrage Fund Direct GrowthHelios

2.98%

₹4 Cr

DSP Nifty Healthcare Index Fund Direct GrowthDSP

2.93%

₹1 Cr

Analyse BIOCON with Orion AI

Ask: "Is Biocon Limited stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Biocon Limited (BIOCON) Stock

Biocon Limited is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE376G01013. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.